Merck-backed QLight opens new Jerusalem nanotech site

Jerusalem Mayor Nir Barkat, who attended the opening, pointed to the new opening as a sign of Jerusalem’s investment.

October 7, 2013 23:31
2 minute read.
Merck-backed QLight opens new Jerusalem nanotech site

nanotech 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


QLight Nanotech, a Jerusalem based start-up backed and partly owned by Merck, opened a new facility in Jerusalem last week to further its development of LED lighting and flat-panel display products using semiconductor nanocrystal materials.

Jerusalem Mayor Nir Barkat, who attended the opening, pointed to the new opening as a sign of Jerusalem’s investment. Qlight is a subsidiary of Yissum, the technology transfer company of the Hebrew University of Jerusalem.

Be the first to know - Join our Facebook page.

“For the past few years we have been focusing on expanding Jerusalem’s hi-tech and biomed industries, which are in the critical path of success for the city,” Barkat said. “The partnership between Qlight Nanotech and Merck is an excellent example of how we can harness the power of Jerusalem’s top institutions, like the Hebrew University, and leverage our applied research to a global marketplace.”

Merck first invested in QLight in 2012, though the companies have not disclosed details of the investment. The agreement called for an additional investment by Merck upon QLight reaching certain development milestones.

“There is ongoing discussion on the next round of investment,” Bernd Reckmann, head of Merck’s chemicals division, told Reuters during a visit to Israel. “It has not yet been decided.”

QLight, which was established in 2009, and Merck have been carrying out joint research into this new class of materials for several years as part of a partnership program supported by the Chief Scientist’s Office.

The new technology will help to innovate the LCD display market, Reckmann said.


“It gives tools to improve the quality of the picture in brightness and color range,” he said. The technology also helps cut energy consumption of flat-screen TVs, Merck said.

While LCD (liquid crystal display) is one of Merck’s biggest cash generators, the German group is also investing in OLED, a display technology that could succeed LCD.

Organic light-emitting diode displays are thinner, more energy efficient and offer higher-contrast images than LCD.

“OLED is still the only technology which has the potential to take market share in the display arena from LCD, but it’s still in its infancy,” Reckmann said. “There are a lot of technical challenges, especially on the manufacturing side.”

Analysts believe OLED will not take significant share – 10 percent or more – of the display market before 2017-18.

The success of technologies such as QLight’s in innovating the LCD market will also make it more difficult for OLED, Reckmann added.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection